Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0006340
UniProt IDP48736
Primary gene name(s)PIK3CG
Synonym gene name(s)unknown
Protein namePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
Protein functionPhosphoinositide-3-kinase, PI3K that phosphorylates PtdIns(4,5P2, Phosphatidylinositol 4,5-bisphosphate to generate phosphatidylinositol 3,4,5-trisphosphate, PIP3. PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G-protein coupled receptor activation to PIP3 production. Involved in immune, inflammatory and allergic responses. Modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. May control leukocyte polarization and migration by regulating the spatial accumulation of PIP3 and by regulating the organization of F-actin formation and integrin-based adhesion at the leading edge. Controls motility of dendritic cells. Together with PIK3CD is involved in natural killer, NK cell development and migration towards the sites of inflammation. Participates in T-lymphocyte migration. Regulates T-lymphocyte proliferation and cytokine production. Together with PIK3CD participates in T-lymphocyte development. Required for B-lymphocyte development and signaling. Together with PIK3CD participates in neutrophil respiratory burst. Together with PIK3CD is involved in neutrophil chemotaxis and extravasation. Together with PIK3CB promotes platelet aggregation and thrombosis. Regulates alpha-IIb/beta-3 integrins, ITGA2B/ ITGB3 adhesive function in platelets downstream of P2Y12 through a lipid kinase activity-independent mechanism. May have also a lipid kinase activity-dependent function in platelet aggregation. Involved in endothelial progenitor cell migration. Negative regulator of cardiac contractility. Modulates cardiac contractility by anchoring protein kinase A, PKA and PDE3B activation, reducing cAMP levels. Regulates cardiac contractility also by promoting beta-adrenergic receptor internalization by binding to GRK2 and by non-muscle tropomyosin phosphorylation. Also has serine/threonine protein kinase activity: both lipid and protein kinase activities are required for beta-adrenergic receptor endocytosis. May also have a scaffolding role in modulating cardiac contractility. Contributes to cardiac hypertrophy under pathological stress. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis. {ECO:0000269|PubMed:12163475, ECO:0000269|PubMed:15294162, ECO:0000269|PubMed:16094730, ECO:0000269|PubMed:21393242, ECO:0000269|PubMed:7624799}.
Subcellular locationCytoplasm {ECO:0000269|PubMed:12163475}. Cell membrane {ECO:0000269|PubMed:12163475}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P48736
Gene Ontology
(Biological Process)
Complete annatation
adaptive immune response [GO:0002250];
angiogenesis [GO:0001525];
cellular response to cAMP [GO:0071320];
cytokine production [GO:0001816];
dendritic cell chemotaxis [GO:0002407];
endocytosis [GO:0006897];
G-protein coupled receptor signaling pathway [GO:0007186];
hepatocyte apoptotic process [GO:0097284];
inflammatory response [GO:0006954];
innate immune response [GO:0045087];
mast cell degranulation [GO:0043303];
natural killer cell chemotaxis [GO:0035747];
negative regulation of cardiac muscle contraction [GO:0055118];
negative regulation of fibroblast apoptotic process [GO:2000270];
negative regulation of triglyceride catabolic process [GO:0010897];
neutrophil chemotaxis [GO:0030593];
neutrophil extravasation [GO:0072672];
phosphatidylinositol 3-kinase signaling [GO:0014065];
phosphatidylinositol biosynthetic process [GO:0006661];
phosphorylation [GO:0016310];
platelet activation [GO:0030168];
platelet aggregation [GO:0070527];
positive regulation of acute inflammatory response [GO:0002675];
positive regulation of cytosolic calcium ion concentration [GO:0007204];
positive regulation of MAP kinase activity [GO:0043406];
positive regulation of protein kinase B signaling [GO:0051897];
regulation of calcium ion transmembrane transport [GO:1903169];
regulation of cell adhesion mediated by integrin [GO:0033628];
respiratory burst involved in defense response [GO:0002679];
secretory granule localization [GO:0032252];
T cell activation [GO:0042110];
T cell chemotaxis [GO:0010818];
T cell proliferation [GO:0042098]
Gene Ontology
(Molecular Function)
Complete annatation
1-phosphatidylinositol-3-kinase activity [GO:0016303];
1-phosphatidylinositol-4-phosphate 3-kinase activity [GO:0035005];
ATP binding [GO:0005524];
ephrin receptor binding [GO:0046875];
phosphatidylinositol 3-kinase activity [GO:0035004];
phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934];
protein kinase activity [GO:0004672];
protein serine/threonine kinase activity [GO:0004674]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytosol [GO:0005829];
mast cell granule [GO:0042629];
membrane [GO:0016020];
phosphatidylinositol 3-kinase complex, class IB [GO:0005944];
plasma membrane [GO:0005886]
Protein-protein interaction111312
Phylogenetic treeP48736
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.03349976250169110.9470618705371610.965883404605578
AZA vs. DISU-0.2570409074277340.3110097820487460.866573281811977
AZA vs. IL7-0.2165549896486720.262904766554870.999311006273513
AZA vs. SAHA-0.0891384324233040.7153959338645860.920271262209552
DISU vs. CD3-0.2341157791759170.6442734908043880.746830098460885
DISU vs. IL70.03111203166723770.9018947959556970.981746326985942
DISU vs. SAHA0.1686872603941320.5631856588950170.857430674701013
DMSO vs. AZA-0.1064688426161990.5275270732063911
DMSO vs. CD3-0.08222366157254960.8709785622448430.911580661401873
DMSO vs. DISU0.1491900817222370.5417436402122380.921635859189505
DMSO vs. IL7-0.1030946814354660.5684637199039510.903436831021822
DMSO vs. SAHA0.009921747381451760.9664959487920410.992876268207915
HIV vs. Mock in Activation0.2387179485003420.8269426171954730.999983755607037
HIV vs. Mock in Latency0.170713865517660.303939777441820.999834320637052
IL7 vs. CD3-0.1753737793289840.728342712017650.816889933936921
SAHA vs. CD3-0.08021399797149720.8735240952484350.91163491103836
SAHA vs. IL70.1242208319707360.6110805653064490.803929869211853
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.279757 0.0368126
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.121 1.552 1.886 2.327 1.829
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB02010 Staurosporine experimental unknown unknown
DB02375 Myricetin experimental unknown unknown
DB05241 XL765 investigational unknown unknown
DB04769 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE experimental unknown unknown
DB06831 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE experimental unknown unknown
DB06836 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE experimental unknown unknown
DB07073 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one experimental unknown unknown
DB07335 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL experimental unknown unknown
DB07503 (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE experimental unknown unknown
DB08059 (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE experimental unknown unknown
DB02656 2-(4-Morpholinyl)-8-Phenyl-4h-1-Benzopyran-4-One experimental unknown unknown
DB08300 1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine experimental unknown unknown
DB04216 Quercetin experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1E8Y X-ray 2.0Å A=144-1102.
1E8Z X-ray 2.4Å A=144-1102.
1HE8 X-ray 3.0Å A=144-1102.
2A4Z X-ray 2.9Å A=144-1102.
2A5U X-ray 2.7Å A=144-1102.
2CHW X-ray 2.6Å A=144-1102.
2CHX X-ray 2.5Å A=144-1102.
2CHZ X-ray 2.6Å A=144-1102.
2V4L X-ray 2.5Å A=144-1102.
3APC X-ray 2.5Å A=144-1102.
3APD X-ray 2.5Å A=144-1102.
3APF X-ray 2.8Å A=144-1102.
3CSF X-ray 2.8Å A=144-1102.
3CST X-ray 3.2Å A=144-1102.
3DBS X-ray 2.8Å A=144-1102.
3DPD X-ray 2.8Å A=144-1102.
3ENE X-ray 2.4Å A=144-1102.
3IBE X-ray 2.8Å A=144-1102.
3L08 X-ray 2.7Å A=144-1102.
3L13 X-ray 3.0Å A=144-1102.
3L16 X-ray 2.9Å A=144-1102.
3L17 X-ray 3.0Å A=144-1102.
3L54 X-ray 2.3Å A=144-1102.
3LJ3 X-ray 2.4Å A=144-1102.
3MJW X-ray 2.8Å A=144-1102.
3ML8 X-ray 2.7Å A=144-1102.
3ML9 X-ray 2.5Å A=144-1102.
3NZS X-ray 2.7Å A=147-1094.
3NZU X-ray 2.6Å A=147-1094.
3OAW X-ray 2.7Å A=144-1102.
3P2B X-ray 3.2Å A=144-1102.
3PRE X-ray 2.9Å A=144-1102.
3PRZ X-ray 2.6Å A=144-1102.
3PS6 X-ray 2.6Å A=144-1102.
3QAQ X-ray 2.9Å A=144-1102.
3QAR X-ray 2.6Å A=144-1102.
3QJZ X-ray 2.9Å A=144-1102.
3QK0 X-ray 2.8Å A=144-1102.
3R7Q X-ray 2.5Å A=144-1102.
3R7R X-ray 2.9Å A=144-1102.
3S2A X-ray 2.5Å A=144-1102.
3SD5 X-ray 3.2Å A=144-1102.
3T8M X-ray 2.5Å A=144-1102.
3TJP X-ray 2.7Å A=144-1102.
3TL5 X-ray 2.7Å A=144-1102.
3ZVV X-ray 2.5Å A=144-1102.
3ZW3 X-ray 2.8Å A=144-1102.
4ANU X-ray 2.8Å A=144-1102.
4ANV X-ray 2.1Å A=144-1102.
4ANW X-ray 2.3Å A=144-1102.
4ANX X-ray 2.7Å A=144-1102.
4AOF X-ray 3.3Å A=144-1102.
4DK5 X-ray 2.9Å A=144-1102.
4EZJ X-ray 2.6Å A=144-1102.
4EZK X-ray 2.8Å A=144-1102.
4EZL X-ray 2.9Å A=144-1102.
4F1S X-ray 3.0Å A=144-1102.
4FA6 X-ray 2.7Å A=144-1102.
4FAD X-ray 2.7Å A=144-1102.
4FHJ X-ray 2.6Å A=144-1102.
4FHK X-ray 3.0Å A=144-1102.
4FJY X-ray 2.9Å A=144-1102.
4FJZ X-ray 3.0Å A=144-1102.
4FLH X-ray 2.6Å A=144-1102.
4FUL X-ray 2.4Å A=144-1102.
4G11 X-ray 3.4Å A=144-1102.
4GB9 X-ray 2.4Å A=144-1102.
4HLE X-ray 2.7Å A=144-1102.
4HVB X-ray 2.3Å A=144-1102.
4J6I X-ray 2.9Å A=144-1102.
4KZ0 X-ray 2.8Å A=144-1102.
4KZC X-ray 3.2Å A=144-1102.
4PS3 X-ray 2.9Å A=144-1102.
4PS7 X-ray 2.6Å A=144-1102.
4PS8 X-ray 2.9Å A=144-1102.
4URK X-ray 2.9Å A=144-1102.
4WWN X-ray 2.7Å A=144-1102.
4WWO X-ray 2.3Å A=144-1102.
4WWP X-ray 2.4Å A=144-1102.
4XX5 X-ray 2.7Å A=144-1102.
4XZ4 X-ray 2.6Å A=144-1102.
5EDS X-ray 2.8Å A=144-1102.
5G2N X-ray 2.6Å A=144-1102.
5G55 X-ray 2.4Å A=144-1102.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Nef interacts with 11289809
Tat activates 17157319
Envelope surface glycoprotein gp120 modulated by 16524887
Envelope surface glycoprotein gp160; precursor inhibits 9808187
Nef involves 26075907
Envelope surface glycoprotein gp160; precursor activates 9341793
HIV-1 virus replication enhanced by expression of human gene 19460752
Envelope surface glycoprotein gp120 mediated by 16081599
Tat interacts with 11154208
Nef complexes with 18854243
Vpr involves 26270987
Tat inhibited by 12077252
Envelope surface glycoprotein gp120 inhibited by 20818790
Envelope surface glycoprotein gp120 relocalizes 18453587
Tat induces phosphorylation of 23301033
Nef downregulates 8636073
Tat regulated by 24073214
Envelope surface glycoprotein gp120 activates 12551992
Envelope surface glycoprotein gp120 regulated by 15689238
Nef activates 25104021
Nef upregulates 10985305

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa00562 Inositol phosphate metabolism - Homo sapiens (human)
hsa01521 EGFR tyrosine kinase inhibitor resistance - Homo sapiens (human)
hsa01522 Endocrine resistance - Homo sapiens (human)
hsa01524 Platinum drug resistance - Homo sapiens (human)
hsa04012 ErbB signaling pathway - Homo sapiens (human)
hsa04014 Ras signaling pathway - Homo sapiens (human)
hsa04015 Rap1 signaling pathway - Homo sapiens (human)
hsa04022 cGMP-PKG signaling pathway - Homo sapiens (human)
hsa04024 cAMP signaling pathway - Homo sapiens (human)
hsa04062 Chemokine signaling pathway - Homo sapiens (human)
hsa04066 HIF-1 signaling pathway - Homo sapiens (human)
hsa04068 FoxO signaling pathway - Homo sapiens (human)
hsa04070 Phosphatidylinositol signaling system - Homo sapiens (human)
hsa04071 Sphingolipid signaling pathway - Homo sapiens (human)
hsa04072 Phospholipase D signaling pathway - Homo sapiens (human)
hsa04150 mTOR signaling pathway - Homo sapiens (human)
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human)
hsa04152 AMPK signaling pathway - Homo sapiens (human)
hsa04210 Apoptosis - Homo sapiens (human)
hsa04211 Longevity regulating pathway - Homo sapiens (human)
hsa04213 Longevity regulating pathway - multiple species - Homo sapiens (human)
hsa04261 Adrenergic signaling in cardiomyocytes - Homo sapiens (human)
hsa04360 Axon guidance - Homo sapiens (human)
hsa04370 VEGF signaling pathway - Homo sapiens (human)
hsa04380 Osteoclast differentiation - Homo sapiens (human)
hsa04510 Focal adhesion - Homo sapiens (human)
hsa04550 Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human)
hsa04611 Platelet activation - Homo sapiens (human)
hsa04620 Toll-like receptor signaling pathway - Homo sapiens (human)
hsa04630 Jak-STAT signaling pathway - Homo sapiens (human)
hsa04650 Natural killer cell mediated cytotoxicity - Homo sapiens (human)
hsa04660 T cell receptor signaling pathway - Homo sapiens (human)
hsa04662 B cell receptor signaling pathway - Homo sapiens (human)
hsa04664 Fc epsilon RI signaling pathway - Homo sapiens (human)
hsa04666 Fc gamma R-mediated phagocytosis - Homo sapiens (human)
hsa04668 TNF signaling pathway - Homo sapiens (human)
hsa04670 Leukocyte transendothelial migration - Homo sapiens (human)
hsa04722 Neurotrophin signaling pathway - Homo sapiens (human)
hsa04725 Cholinergic synapse - Homo sapiens (human)
hsa04750 Inflammatory mediator regulation of TRP channels - Homo sapiens (human)
hsa04810 Regulation of actin cytoskeleton - Homo sapiens (human)
hsa04910 Insulin signaling pathway - Homo sapiens (human)
hsa04914 Progesterone-mediated oocyte maturation - Homo sapiens (human)
hsa04915 Estrogen signaling pathway - Homo sapiens (human)
hsa04917 Prolactin signaling pathway - Homo sapiens (human)
hsa04919 Thyroid hormone signaling pathway - Homo sapiens (human)
hsa04921 Oxytocin signaling pathway - Homo sapiens (human)
hsa04923 Regulation of lipolysis in adipocytes - Homo sapiens (human)
hsa04930 Type II diabetes mellitus - Homo sapiens (human)
hsa04931 Insulin resistance - Homo sapiens (human)
hsa04932 Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human)
hsa04933 AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human)
hsa04960 Aldosterone-regulated sodium reabsorption - Homo sapiens (human)
hsa04973 Carbohydrate digestion and absorption - Homo sapiens (human)
hsa05100 Bacterial invasion of epithelial cells - Homo sapiens (human)
hsa05142 Chagas disease (American trypanosomiasis) - Homo sapiens (human)
hsa05145 Toxoplasmosis - Homo sapiens (human)
hsa05146 Amoebiasis - Homo sapiens (human)
hsa05160 Hepatitis C - Homo sapiens (human)
hsa05161 Hepatitis B - Homo sapiens (human)
hsa05162 Measles - Homo sapiens (human)
hsa05164 Influenza A - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)
hsa05205 Proteoglycans in cancer - Homo sapiens (human)
hsa05210 Colorectal cancer - Homo sapiens (human)
hsa05211 Renal cell carcinoma - Homo sapiens (human)
hsa05212 Pancreatic cancer - Homo sapiens (human)
hsa05213 Endometrial cancer - Homo sapiens (human)
hsa05214 Glioma - Homo sapiens (human)
hsa05215 Prostate cancer - Homo sapiens (human)
hsa05218 Melanoma - Homo sapiens (human)
hsa05220 Chronic myeloid leukemia - Homo sapiens (human)
hsa05221 Acute myeloid leukemia - Homo sapiens (human)
hsa05222 Small cell lung cancer - Homo sapiens (human)
hsa05223 Non-small cell lung cancer - Homo sapiens (human)
hsa05224 Breast cancer - Homo sapiens (human)
hsa05230 Central carbon metabolism in cancer - Homo sapiens (human)
hsa05231 Choline metabolism in cancer - Homo sapiens (human)